OCUGEN INC OCGN 深 滬
等待開盤 09-25 09:30:00 美东时间
1.00
0.000
0.00%
華盛通- 最 高1.02
- 今 開0.995
- 成交量 564.51万股
- 最 低 0.9701
- 昨 收 1.00
- 總市值 3.39亿
- 52周最高 2.725
- 市盈率 靜 --
- 換手率 1.66%
- 52周最低 0.97
- 委 比 -40.72%
- 總股本 3.39亿
- 歷史最高 18.77
- 量 比 0.69
- 振 幅 4.99%
- 歷史最低 0.17
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ocugen Stockholders Approve Meeting Adjournment for Share Increase
An announcement from Ocugen ( ($OCGN) ) is now available. On September 21, 2026...
09-23 18:35
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
What's Happening With Ocugen Stock Thursday?
Shares of Ocugen Inc. (NASDAQ:OCGN) are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data. Ocugen stock is gaining positive traction. Why are OCGN shares climbing? Interim Analysis Shows Negative Treatment Effect in Key Gene Therapy Trial The pr...
09-10 21:43
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
09-10 18:27
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS, Inc. announced the appointment of Sanjay Subramanian as Chief Financial Officer, effective September 9, 2026, succeeding Ivor Macleod, who is retiring. Subramanian brings over 20 years of experience in finance and business development across the biotech and pharmaceutical sectors. Macleod, who joined SCYNEXIS in 2022, will remain through October 9 to ensure a smooth transition. Subramanian was granted an option to purchase 100,000 share...
09-10 12:00
Ocugen to Share Ophthalmic Gene Therapy Progress
Ocugen ( ($OCGN) ) has shared an update. On September 8, 2026, Ocugen said it w...
09-09 06:09
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA) U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and...
09-01 19:06
Ocugen to Participate in Upcoming September Investor and Industry Conferences
Ocugen, Inc. will present its innovative modifier gene therapy platform at three upcoming conferences in September 2026. Dr. Shankar Musunuri, Ocugen's CEO, will participate in fireside chats at the Citi Biopharma Back to School Conference on September 9 and the H.C. Wainwright Global Investment Conference on September 15, both in New York City. On September 24, Dr. Raj K. Maturi will present on the Phase 2 results of OCU410 gene therapy for geog...
08-25 11:02
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market
Ocugen Inc ($OCGN) announced an update on their ongoing clinical study. Ocugen ...
08-20 00:31
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate OCU410’s regulatory path while further differentiating its one-time treatment for life approa...
07-29 19:13
